Publications

  1. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 03. PMID: 32497499. View in: PubMed
  2. Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020 Jun 01; 112(6):562-573. PMID: 32145020. View in: PubMed   
  3. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 May 06. PMID: 32376655. View in: PubMed
  4. Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer. 2020 May; 8(1). PMID: 32376721. View in: PubMed
  5. Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020 Mar 31. PMID: 32233107. View in: PubMed
  6. de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-18. PMID: 32343604. View in: PubMed
  7. Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL. Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell. 2020 Feb 20; 180(4):749-763.e13. PMID: 32059780.  View in: PubMed
  8. Nicholson LT, Fong L. Immune Checkpoint Inhibition in Prostate Cancer. Trends Cancer. 2020 Mar; 6(3):174-177. PMID: 32101720. View in: PubMed
  9. Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 04; 31(4):532-540. PMID: 32147213.View in: PubMed
  10. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Front Immunol. 2019; 10:2985. PMID: 31993050. View in: PubMed
  11. Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 Feb; 8(2):246-254. PMID: 31852717. View in: PubMed
  12. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 Jan; 10(1):40-53. PMID: 31732494. View in: PubMed
  13. McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, Liu G. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol. 2019 Dec 20; 37(36):3507-3517. PMID: 31644357. View in: PubMed
  14. Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 Oct 18; 7(1):267. PMID: 31627733. View in: PubMed
  15. Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. JAMA Oncol. 2019 Jun 02. PMID: 31154457. View in: PubMed
  16. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976. PMID: 31050707. View in: PubMed
  17. Poggio M, HuT, PaiCC, ChuB, BelairCD, ChangA, MontabanaE, Lang UE, FuQ, Fong L, Blelloch R. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell, 2019 4;177(2):414-427.e13.2019. [PMID:30951669]
  18. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [PMID:30321406]
  19. Pai CC, Huang JT, Lu X, Simons DM, Park C, Chang A, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises anti-tumor efficacy in low tumor burden states. Immunity, 2019 Feb 19;50(2):477-492.e8. [PMID:30737146]
  20. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2018 Sep 24. pii: S1558-7673(18)30629-3. [PMID:30327180]
  21. Pai CC, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 Jan 2;129(1):349-363. doi: 10.1172/JCI123391. [PMID:30530991]
  22. Oh D, Fong L. Immunity in Times of Metastasis.  Immunity, 2018 Dec 18;49(6):1002-1003. doi: 10.1016/j.immuni.2018.12.008. [PMID:30566878]
  23. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. [PMID:30340047]
  24. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 Oct 17;29(10):3476-3482. [PMID:30227708]
  25. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunol. 2018 Oct 1;8(1):e1486953. [PMID: 30546940]
  26. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep. 2018 Jun 12;23(11):3262-3274. [PMID:29898397].
  27. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. Clinical Variables Associated with Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2017 Dec 27. pii: S1558-7673(17)30390-7. [PMID: 29352713]
  28. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.  Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase 3 Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Onc 2018 JCO2017769562. doi: 10.1200/JCO.2017.76.9562. [PMID:29590008].
  29. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. [PMID:29867230]   
  30. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer. The Oncologist 2018; 23:656-e64 
  31. Patel A, Fong L. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies. Oncology. 2018 Jun;32(6):e65-e73. [PMID: 29940064
  32. Patel A, Fong L. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines. Oncology. 2018 Mar 15;32(3):112-20. [PMID:29548065]
  33. Cha E, Fong L. Shuffling the deck with CTLA-4 therapy: deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients. Oncoimmunol 10.4161/21624011.2014.956016, 2014.
  34. Mariathasan S, Turley S, Nickles D, Kadel EE, Koeppen H, Yuen K, Castiglioni A, Astarita J, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Lianoglou S, Eriksson P, Hoglund M, Somarriba L, Halligan DL, van der Heijden M, Loriot Y, Rosenberg J, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. A balance of genomic instability, tumour-immune topography and TGF-β signaling governs response to PD-L1 blockade in metastatic bladder cancer. Nature. 2018 doi: 10.1038/nature25501. [PMID: 29443960].
  35. Truillet C, Oh HL, Yeo SP, Lee CY, Huynh L, Wei J, Parker M, Blakely C, Sevillano N, Wang YH, Shen Y, Olivas V, Jami K, Moroz A, Jego B, Jaumin E, Fong L, Craik C, Chang A, Bivona T, Wang CI, Evans M. Imaging PD-L1 expression with immunoPET. Bioconjug Chem 2017 doi: 10.1021/acs.bioconjchem.7b00631. [PMID: 29125731]
  36. Sun Z, Wang CY, Lawson DA, Kwek S, Velozo HG, Owyong M, Lai M, Fong L, Wilson M, Su H, Werb Z, Cooke DL. Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells. Oncotarget 2018 (13):10945-10961. [PMID:29541388].
  37. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 3. pii: S1558-7673(17)30163-5.  [PMID:28655452]
  38. Bakhru P, Zhu ML, Wong HH, Hong LK, Khan I, Mouchess M, Gulati A, Starmer J, Hou Y, Sailer D, Fong L, Anderson MS, Su MA. Combination central tolerance and peripheral checkpoint blockade unleashes anti-melanoma immunity. JCI Insight, 2017 Sep 21;2(18). pii: 93265. doi: 10.1172/jci.insight.93265. [PMID: 28931755]
  39. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Comm. 2017 doi:10.1038/s41467-017-00608-2. [PMID:28928380]
  40. Cabana MD, McKean M, Caughey AB, Fong L, Lynch S, Wong A, Leong R, Boushey HA, Hilton JF. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics. 2017 Sep;140(3). pii: e20163000. doi: 10.1542/peds.2016-3000. Epub 2017 Aug 7. [PMID:28784701]
  41. Thimmig, LM, Cabana MD, Bentz MG, Potocka K, Beck A, Fong L, Chao C, Caughey AB, Leong RE, Wong A, McKean M. Television During Meals in the First Four Years of Life. Clin Peds, 56(7):659-666, 2016. [PMID:28503997]
  42. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Andrea Necchi A, Gerritsen W, Gurney H, Quinn DL, Culine S, Sternberg CN, Mai Y, Poehlein C, Perini RF, Dean F. Bajorin DF. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. [PMID:28212060]
  43. Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T cell repertoire. Can Res, 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. [PMID:28031229]
  44. Zhang L, Cham J, Paciorek A, Trager J, Sheikh N, Fong L. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. BMC Bioinformatics. 2017 Feb 27;18(1):129. doi: 10.1186/s12859-017-1544-9. [PMID:28241742]
  45. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC,Fong L, Nolan GP, Engleman EG. Systemic immunity is required for effective cancer immunotherapy. Cell, 2017 Jan 26;168(3):487-502.e15. [PMID:28111070]
  46. Kim W, Fong L. Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol 35(1):4- 01 Jan 2017.
  47. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016 Dec 20;4:92. [PMID:28031820]
  48. Choueiri T, Fishman M, Escudier B, McDermott D, Drake C, Kluger H, Stadler W, Perez-Gracia JL, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Albiges L, Cohen L, Young T, Chasalow S, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland J, Simon J, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Can Res, 22(22):5461-5471, 2016. [PMID:27169994]
  49. WeiXX, ChanS, KwekS, LewisJ, Dao V, ZhangL, CooperbergMR, RyanCJ, LinAM, FriedlanderT, RiniB, SimkoJP, CarrollPR, SmallEJ, Fong L. Recruitment of effector T cells into the tumor microenvironment with neoadjuvant systemic GM-CSF in patients with localized prostate cancer. Can Immunol Res, 4(11):948-958, 2016. [PMID:27688020]
  50. Wattenberg MM, Fong L, Madan RA, Gulley JL. Immunotherapy in genitourinary malignancies. Curr Opin Urol. 26(6):501-7, 2016. [PMID:27471994]
  51. Sheikh N, Cham J, ZhangL, Devries T, LetarteS, HammD, TragerJ, Fong L. Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects. Can Res, 76(13):3711-8, 2016. [PMID: 27216195]
  52. Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor. Urol Oncol, 2014. [PMID:24495446]
  53. Wei XX, Fong L, Small EJ. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016 Mar;16(3):421-32. [PMID: 26698365]
  54. Kwek S, Kahn J, Greaney S, Lewis J, Cha E, Zhang L, Weber R, Leonard L, Markovic SN, Fong L, Spitler LE. GM-CSF and Ipilimumab Therapy in Metastatic Melanoma: Clinical Outcomes and Immunologic Responses.  Oncoimmunology, 5(4):e1101204, 2015. [PMID: 27141383]
  55. Kwek S, Lewis J, Zhang Li, Harzstark AL, Weinberg VK, Ryan CJ, Lin AM, Small EJ, Fong L. Pre-existing levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab.  Can Immunol Res, 2015. [PMID: 25968455]
  56. Small EJ, Lance R, Gardner TA, Karsh LI, Fong L, McCoy C, De Vries T, Sheikh N, GuhaThakurta D, Chang N, Redfern CH, Shore ND. D. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Can Res, 21(17):3862-9, 2015. [PMID: 25925891]
  57. Oh DY, Venook AP, Fong L. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw, 13(8):970-8, 2015. [PMID: 26285242]
  58. Landegren N, Donald SharonD, Shum AK, Khan IS, FasanoK, HallgrenA, Kampf C, FreyhultE, Ardesjö-LundgrenB, AlimohammadiM, RathsmanS, LudvigssonJF, HedelinH, LundhD, MotrichR, RiveroV, Fong L, GiwercmanA, GustafssonJ, Perheentupa J, HusebyeES, Anderson MS, Snyder M, Kämpe O. Transglutaminase 4 as a prostate autoantigen in male subfertility. Science Trans Med, (292):292ra101, 2015. [PMID: 26084804]
  59. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015;14(12):1529-41. [PMID: 26488270]
  60. Kim W, Zhang L, Wilton J, Fetterly G, Mohler J, Weinberg V, Morse A, Szmulewitz R, Friedlander T, Fong L, Lin A, Harzstark A, Molina A, Small E, Ryan A. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Can Res, 2014. [PMID:25336698]
  61. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. J Natl Cancer Inst, 106(11), 2014. [PMID:25255802]
  62. Crane CA, Austgen KM, Hofmann C, Avaneysan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL. Tumor immune evasion by lactate dehydrogenase induction of NKG2D ligands on myeloid cells in cancer patients. Proc Natl Acad Sci, 111(35):12823-8, 2014. [PMID:25136121]
  63. Cha E, Klinger M, Hou Y, Ribas A, Farham M, Fong L. T cell receptor turnover induced by anti-CTLA4 antibody treatment in cancer patients. Sci Trans Med, 6:238ra70, 2014. [PMID: 24871131]
  64. Khan IS, Mouchess ML, Zhu M, Conley, Fasano KJ, Hou Y, Fong L, Su MA, Anderson MS. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med, 211(5):761-8, 2014. [PMID: 24752296]
  65. Friedlander T, Fong L. The End of the Beginning: Circulating Tumor Cells as a Biomarker in Castration Resistant Prostate Cancer. J Clin Onc, 32(11):1104-6, 2014. [PMID: 24616311]
  66. Cheng ML, Fong L. Beyond sipuleucel-T: Immune approaches to treating prostate cancer. Curr Treat Op Oncol, 2014. [PMID:24402184]
  67. Cheng ML, Fong L. Effects of RANKL-targeted therapy in immunity and cancer. Frontiers in Oncol, 3:329, 2014. [PMID:24432249]
  68. Kelley, RK, Magbanua M, Ko AH, Huang J, Siah I, Watt L, Beuner JH, Christner SM, Egorin MJ, Fong L, Yeh BM, Moore AP, Park JW, Korn WM, Tempero MA, Venook AP, Hanahan D, Bergsland EK. Metronomic Cyclophosphamide, Imatinib, and Bevacizumab to Target Tumor Angiogenesis in Advanced Colorectal Cancer: A Phase 1 Trial with Pharmacokinetic and Biomarker Analyses. Br J Cancer, 109(7):1725-34, 2013 [PMID: 24022191]
  69. Kwek S, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol, 189(7):3759-66, 2012. [PMID:22956585]
  70. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study. Urol Oncol 30(4):408-14, 2012. [PMID: 20884247]
  71. Kwek S, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA-4 blockade. Nat Rev Cancer, 12(4):289-97, 2012. [PMID:22378189]
  72. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep 27(1):3-9, 2012. [PMID:21971890]
  73. Cha E, Fong L. Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches. J Clin Oncol, 29(27):3677-85, 2011. [PMID:21825260].
  74. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer, 117(18):4194-200, 2011. [PMID: 21387258]
  75. Kapadia D, Sadikovic A, Vanloubbeeck Y, Brockstedt D, Fong L. Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses. PLoS One, 6; 4: e19376, 2011. [PMID:21559416]
  76. Moltzahn F, Olshen A, Haehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton, J, Carroll P, Blelloch R. Microfluidic based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in sera of prostate cancer patients. Can Res, 15;71(2):550-60, 2011. [PMID: 21098088]
  77. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti FG, Bluestone JA, Stock PG. Islet Transplantation in type I diabetics using calcineurin inhibitor-free immunosuppressive protocols based on T cell adhesion or costimulation blockade. Transplantation;90(12):1595-601, 2010. [PMID: 20978464]
  78. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet Transplantation in type I diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant, 10: 1870–1880, 2010. [PMID: 20659093]
  79. Chung K, Gore I, Fong L, Vennok A, Beck SB, Dorazio P, Crisciteiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. A Phase II Study of the Anti-CTLA4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. J Clin Oncol, 28(21):3485-90, 2010. [PMID: 20498386]
  80. Olson BM, Frye TP, Johnson LE, Fong L, KnutsonKL, DisisML, McNeel DG. HLA-A2-Restricted T-Cell Epitopes Specific for Prostatic Acid Phosphatase. Cancer Immunol Immunother, 59(6):943-53, 2010. [PMID: 20140431]
  81. DeVoss JJ, Leclair NP, Hou Y, Grewal NK, Johannes KP, Lu W, Yang T, Meagher C, Fong L, Strauss EC, Anderson MS. An autoimmune response to OBP1a is associated with dry eye in the Aire-deficient mouse. J Immunol, 184:4236-46, 2010. [PMID: 20237294]
  82. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP 17 inhibitor abiraterone acetate (CB7630), Demonstrating clinical activity in castration-resistant prostate cancer patients with prior ketoconazole therapy. J Clin Oncol, 28:1481-1488, 2010. [PMID: 20159824]
  83. Small EJ, Fong L. Developing Immunotherapy as Legitimate Therapy for Prostate Cancer Patients. J Clin Oncol, 28(7): 1085–1087, 2010. [PMID: 20100956]
  84. Cha E, Fong L.  Therapeutic Vaccines for Prostate Cancer.  Curr Opin Mol Ther, 1: 77-85, 2010. [PMID: 20140819]
  85. Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O’Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Science- Transl Med, 1:9ra20, 2009. [PMID: 20368189]
  86. Chien AJ, Illi JA, Ko A, Korn W, Fong L, Chen L, Kashani-Sabet M, Ryan C, Rosenberg J, Dubey S, Small E, Jahan T, Hylton N, Yeh B, Huang Y, Koch K, Moasser MM.   A phase 1 study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies.   Clin Can Res 17: 5569-5575, 2009. [PMID: 19706807]
  87. Hou Y, Devoss J, Dao V, Kwek SS, Simko J, McNeel D, Anderson MS, Fong L. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.  J Clin Invest 119: 2031-2041, 2009. [PMID: 19603556]
  88. Fong L, Kwek SS, O’Brien S, Kavanagh B, Weinberg V, Lin A, Rosenberg J, Ryan CJ, McNeel D, Rini B, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69, 609-615, 2009. [PMID: 19147575]
  89. Fong L, Small EJ.  Anti-CTLA4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment.  J Clin Oncol 26(32) 5275-5283, 2008. [PMID: 18838703]
  90. Kavanagh B, O’Brien S, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112(4):1175-83, 2008. [PMID: 18523152]
  91. Fasso M, Waitz R, Rim T, Hou Y, Greenberg NM, Shastri N, Fong L, Allison JP.  SPAS-1 (stimulator of prostatic adenocarcinoma specific T cells-1)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci 105(9):3509-14, 2008. [PMID: 18303116]
  92. Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol 180(3):1526-34, 2008. [PMID: 18209048]
  93. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.  J Urol 178(6):2372-6, 2007. [PMID: 17936834]
  94. Kavanagh B, Ko A, Venook A, MargolinK, ZehH, LotzeM, Schillinger B, LiuW, LuY, Mitsky P, ShillingM, BercoviciN, Loudovaris M, GuillermoR, LeeSM, BenderJ, MillsB, Fong L.  Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunoth 30(7):762-772, 2007. [PMID: 17893568]
  95. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep 9(3):226-33, 2007. [PMID: 17430695]
  96. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clin Cancer Res 13(6):1810-5, 2007. [PMID: 17363537]
  97. Devoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi R, Fong L, Anderson MS.  Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 203(12):2727-35, 2006. [PMID: 17116738]
  98. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98(4):763-9, 2006. . [PMID: 16796694]
  99. Rini BI, Weinberg V, Fong L, Conry S, Hershberg R, and Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.  Cancer 107(1):67-74, 2006. [PMID: 16736512]
  100. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, and Wilding G, A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. Mol Ther 14(1):107-17, 2006. [PMID: 16690359]
  101. Rini BI, Fong L, Weinberg V, Kavanagh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6):2087-91, 2006. [PMID: 16697809]
  102. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep 7(3):239-46, 2006.
  103. Kapadia D, Fong L.  CTLA4 blockade: Autoimmunity as treatment. J Clin Oncol 23(35):8926-8, 2005. [PMID: 16204008]
  104. Fong L. Small EJ. Immunotherapy for prostate cancer.  Sem Oncol 30(5): 649-658, 2003. [PMID: 14571412]
  105. Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 106(1):10-5, 2003.
  106. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol 76(21):11033-41, 2002. [PMID: 12368346]
  107. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic antitumor immunity. Blood 99(5):1676-82, 2002. [PMID: 11861283]
  108. Fong L, Brockstedt DG, Benike C, Strang G, Smits B, Ruegg CL, Engleman EG Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167: 7150-7156, 2001. [PMID: 11739538]
  109. Fong L, Hao Y, Rivas A, Benike C, Yuen A, Fisher G, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci 98(15):8809-14, 2001. [PMID: 11427731]
  110. Fong L, Brockstedt DG, Benike C, Wu L, Engleman EG.   Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259, 2001. [PMID: 11238679]
  111. Merad M, Fong L, Bogenberger J, Engleman EG. Differentiation of myeloid dendritic cells into CD8a-positive dendritic cells in vivo. Blood 96(5):1865-72, 2000. [PMID: 10961888]
  112. Fong L and Engleman EG.  Dendritic cells in cancer immunotherapy.  Ann Rev Immunol 18:245-273, 2000. [PMID: 10837059]
  113. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG.  Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92(1):67-75, 1999. [PMID: 10413654]
  114. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.  Nat Med 5(6):677-685, 1999. [PMID: 10371507]
  115. Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. Transplantation 66(5):585-93, 1998. [PMID: 9753336]
  116. Fong L, Ruegg C, Brockstedt DG, Engleman EG, Laus R. Cutting Edge: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for prostate cancer immunotherapy. J Immunol 159:3113-3118, 1997. [PMID: 9317107]
  117. Kim DT, Mitchell D, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB.  Introduction of soluble proteins into both MHC class I and II pathways by conjugation to a HIV tat peptide.  J Immunol 159:1666-68,1997. [PMID: 9257826]

  118. Yang H, Cham J, Neal B, Fan Z, He T, Zhang L. (2023). NAIR: Network Analysis of Immune Repertoire. Frontiers in Immunology. 14. 10.3389/fimmu.2023.1181825.